Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T22:12:48.108Z.
Calculation as of: 2026-10-06T22:12:48.108Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5b41231b7583dd96ab78187317b9f32b3728f458d8f95d0d00832bd8f136f307
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Neumora Therapeutics, Inc. Common Stock
Market Cap
$87.27M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$87.85M
EV/Sales Ratio
15.26x
TTM Avg
5.59x
3Y Avg
5.59x
5Y Avg
17.86x
Market Cap
$90.20M
EV/Sales Ratio
3.06x
TTM Avg
2.76x
3Y Avg
2.60x
5Y Avg
2.86x
Market Cap
$84.13M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neumora Therapeutics, Inc. Common Stock (NMRA) | $87.27M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $87.85M | 15.26x | 5.59x | 5.59x | 17.86x |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 1.00x | 1.01x | 0.60x | 0.55x |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $89.44M | 2.45x | 1.93x | 2.28x | 2.11x |
| Equillium, Inc. (EQ)vs › | $89.78M | N/A | 3.31x | 1.36x | 1.36x |
| ImmuCell Corporation (ICCC)vs › | $90.20M | 3.06x | 2.76x | 2.60x | 2.86x |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | N/A | N/A | N/A | N/A |
| Rallybio Corporation (RLYB)vs › | $90.64M | N/A | 28.63x | 35.79x | 35.79x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
